154 related articles for article (PubMed ID: 38508214)
21. A novel phenotype in a family with autosomal dominant retinal dystrophy due to c.1430A > G in retinoid isomerohydrolase (RPE65) and c.37C > T in bestrophin 1 (BEST1).
Pappalardo J; Heath Jeffery RC; Thompson JA; Chelva E; Pham Q; Constable IJ; McLaren TL; Lamey TM; De Roach JN; Chen FK
Doc Ophthalmol; 2021 Aug; 143(1):61-73. PubMed ID: 33512609
[TBL] [Abstract][Full Text] [Related]
22. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl.
Bennett J; Maguire AM
Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477G mutation in
Jauregui R; Cho A; Oh JK; Tanaka AJ; Sparrow JR; Tsang SH
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 32014860
[TBL] [Abstract][Full Text] [Related]
24. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
25. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
26. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
Kwak JJ; Kim HR; Byeon SH
Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
[TBL] [Abstract][Full Text] [Related]
27. [RPE65-retinal Dystrophies: From the Spectrum of the Clinical Picture to Gene Therapy].
Stingl K; Priglinger C
Klin Monbl Augenheilkd; 2024 Mar; 241(3):257-258. PubMed ID: 38508213
[No Abstract] [Full Text] [Related]
28. The clinical features of retinal disease due to a dominant mutation in RPE65.
Hull S; Mukherjee R; Holder GE; Moore AT; Webster AR
Mol Vis; 2016; 22():626-35. PubMed ID: 27307694
[TBL] [Abstract][Full Text] [Related]
29. Voretigene neparvovec-rzyl for treatment of
Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
[No Abstract] [Full Text] [Related]
30. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
Kessel L; Christensen UC; Klemp K
Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.
Levi SR; Oh JK; de Carvalho JRL; Mahajan VB; Tsang SH; Sparrow JR
JAMA Ophthalmol; 2020 Aug; 138(8):919-921. PubMed ID: 32556084
[No Abstract] [Full Text] [Related]
32. A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice.
Murro V; Banfi S; Testa F; Iarossi G; Falsini B; Sodi A; Signorini S; Iolascon A; Russo R; Mucciolo DP; Caputo R; Bacci GM; Bargiacchi S; Turco S; Fortini S; Simonelli F
Orphanet J Rare Dis; 2023 Jul; 18(1):223. PubMed ID: 37525225
[TBL] [Abstract][Full Text] [Related]
33. RPE65-related retinal dystrophy: Mutational and phenotypic spectrum in 45 affected patients.
Lopez-Rodriguez R; Lantero E; Blanco-Kelly F; Avila-Fernandez A; Martin Merida I; Del Pozo-Valero M; Perea-Romero I; Zurita O; Jiménez-Rolando B; Swafiri ST; Riveiro-Alvarez R; Trujillo-Tiebas MJ; Carreño Salas E; García-Sandoval B; Corton M; Ayuso C
Exp Eye Res; 2021 Nov; 212():108761. PubMed ID: 34492281
[TBL] [Abstract][Full Text] [Related]
34. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
[TBL] [Abstract][Full Text] [Related]
35. The Marshall M. Parks memorial lecture: making sense of early-onset childhood retinal dystrophies--the clinical phenotype of Leber congenital amaurosis.
Traboulsi EI
Br J Ophthalmol; 2010 Oct; 94(10):1281-7. PubMed ID: 19825837
[TBL] [Abstract][Full Text] [Related]
36. Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A).
Ding Y; Carvalho E; Murphy C; McInerney V; Krawczyk J; O'Brien T; Howard L; Cai L; Shen S
Stem Cell Res; 2020 Mar; 43():101665. PubMed ID: 31954326
[TBL] [Abstract][Full Text] [Related]
37. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
38. Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.
Lee K; Garg S
Genet Med; 2015 Apr; 17(4):245-52. PubMed ID: 25790163
[TBL] [Abstract][Full Text] [Related]
39. Inherited Retinal Diseases Due to
Aoun M; Passerini I; Chiurazzi P; Karali M; De Rienzo I; Sartor G; Murro V; Filimonova N; Seri M; Banfi S
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281261
[TBL] [Abstract][Full Text] [Related]
40. The new landscape of retinal gene therapy.
Ku CA; Pennesi ME
Am J Med Genet C Semin Med Genet; 2020 Sep; 184(3):846-859. PubMed ID: 32888388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
